abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

One year in review 2019: psoriatic arthritis


Clin Exp Rheumatol. Nov-Dec 2020;38(6):1046-1055. Epub 2020 Nov 17.

Emanuele Calabresi 1, Sara Monti 2, Riccardo Terenzi 3, Giovanni Zanframundo 2, Simone Perniola 4, Linda Carli 5

Author Information

1 Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

2 University of Pavia and IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

3 USL Toscana Centro, Firenze, Italy.

4 Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.

5 Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. 81clinda@gmail.com.


Psoriatic arthritis (PsA) is an inflammatory arthritis belonging to spondyloarthritides (SpA), a group of rheumatologic diseases characterised bya wide spectrum of different clinical manifestations that tend to associate with various comorbidities and that may significantly compromise the quality of life of patients. Nowadays, it is well known how PsA may manifest in different clinical domains, in particular peripheral articular and periarticular involvement, axial involvement, skin and nail psoriasis. Moreover, the majority of patients with PsA develop comorbidities such as inflammatory bowel diseases, uveitis, but also cardiovascular diseases, psychiatric or pulmonary pathologies. The therapeutical armamentarium of PsA has been enriched during the last years, in relation to an advance in the knowledge of the immunological mechanisms at the basis of the disease; in particular, the future frontier of "personalised medicine" could lead to a further improvement in the quality of care of this group of patients. In this paper we review the literature on PsA of 2019 (Medline search of articles published from 1st January 2019 to 31st December 2019).